Tesofensine: Appetite, Weight, and the Open Questions
A triple-reuptake inhibitor whose striking phase 2 weight loss is shadowed by safety signals and a Lancet expression of concern.
Tesofensine periodically resurfaces in discussions of weight-loss pharmacology, often described in glowing terms. It is worth a careful, sober look — not because it is a peptide in the strict sense (it isn’t), but because it sits squarely in the appetite-and-weight conversation, and because the gap between its early promise and its unresolved questions is instructive.
What it is and what the trial showed
Tesofensine is a triple monoamine reuptake inhibitor — it blocks reuptake of noradrenaline, dopamine, and serotonin, neurotransmitters tied to appetite and reward. The intended effect is to reduce appetite centrally, in the brain, rather than by acting on the gut.
The headline evidence is a single phase 2 trial: Astrup and colleagues, published in The Lancet in 2008 (volume 372, pages 1906–1913). This 24-week randomised, double-blind, placebo-controlled study in obese patients tested three doses. Mean weight loss was roughly 5% at 0.25 mg, 9% at 0.5 mg, and 11% at 1 mg, against about 2% on placebo. The 0.5 mg dose produced roughly 10% placebo-subtracted loss — about double what then-approved obesity drugs achieved.
Tesofensine’s striking weight-loss numbers come from one phase 2 trial — and that trial later drew a formal Lancet expression of concern over how its adverse events were recorded. Striking early results are exactly where the hardest questions usually remain open.
The open questions
| Concern | What the evidence shows |
|---|---|
| Cardiovascular | The trial reported increased heart rate at 0.5 mg and 1 mg; blood pressure signals raised regulatory caution |
| Psychiatric | Mood-related adverse events were a flagged concern for a drug acting on dopamine and serotonin |
| Data integrity | A 2013 Lancet expression of concern, prompted by a Danish regulatory inspection, noted the published side-effect profile may not reflect the trial’s actual course |
| Scale of evidence | Phase 3 development did not proceed in the US or EU; the cardiovascular signal would have required a dedicated outcomes trial |
The expression of concern
In 2013, following a Danish Health and Medicines Authority inspection, The Lancet published an expression of concern about the 2008 trial. The inspection found, among other issues, that some pre-randomisation conditions such as headache and depression were not consistently registered as adverse events — meaning the published safety picture may understate harms. That concern adds uncertainty precisely where this drug most needs reassurance.
A note on framing
Tesofensine sometimes appears in gray-market settings as a powerful, underappreciated tool. That framing foregrounds the efficacy and omits the cardiovascular signal, the data-integrity flag, and the absence of broad approval. Both halves belong in any honest account — especially now that better-studied GLP-1 therapies have raised the bar.
The takeaway
Tesofensine produced impressive weight loss in one phase 2 trial — but that trial carries an unresolved Lancet expression of concern, the safety database shows cardiovascular and psychiatric signals, and it never cleared phase 3 in major markets. It is not an established, broadly approved obesity treatment. Treat the enthusiastic version with the skepticism any “promising but unproven” story deserves.
Sources
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients (Astrup et al., Lancet 2008)
- Trial irregularities earn Lancet tesofensine study an Expression of Concern (Retraction Watch)
- New antiobesity drug, tesofensine, shows good phase II results (Nature Reviews)